InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,246.68
(
0.48%
)
US TECH 100
17,852.00
(
0.73%
)
Dow Jones
39,558.11
(
0.32%
)
Brent Oil
82.28
(
-1.12%
)
Bitcoin
61,603.61
(
-2.07%
)
Post# of 251820
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: JohnWayne post# 218590

Wednesday, 04/18/2018 10:58:53 PM

Wednesday, April 18, 2018 10:58:53 PM

Post# of 251820
Ok, I see you were talking about OS co-primary endpoint. The reason BMY selected that is most likely to preserve CheckMate-227 Part 1a trial (Nivolumab + ipilimumab vs Nivolumab vs chemo in PD-L1+) completely. In case PFS co-primary in TMB fails or regulators consider it post hoc, they at least have something to fall on based entirely on prespecificed portion of trial.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up